Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1983 Jun;71(6):1842–1853. doi: 10.1172/JCI110940

Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.

B Warner, T J Worgul, J Drago, L Demers, M Dufau, D Max, R J Santen
PMCID: PMC370390  PMID: 6408125

Abstract

Potent synthetic analogs of gonadotropin-releasing hormone produce parodoxical antireproductive effects when administered chronically. These compounds are minimally toxic and may exhibit no plateau of the dose-response curve even at very high doses. These considerations served as the basis for our systematic evaluation of [D-leucine6-desarginine-glycine-NH2(10)]gonadotropin-releasing hormone (GnRH-A) proethylamide in the very high dose range (i.e., 10-fold larger amounts than previously used). In rats given the analog for 12 wk, prostate, testis, and seminal vesicle weights were suppressed to a greater extent with 200 micrograms q.d. than with 40 micrograms q.d. (P less than 0.01 prostate, less than 0.01 testis, less than 0.01 seminal vesicles), indicating dose-response effects in the very high dose range. 200 micrograms of [D-Leu6-des-Gly-NH2(10]-GnRH-A consistently suppressed leutinizing hormone (LH) values at 6 and 12 wk (basal 71 +/- 9.5; 6 wk 34 +/- 3.8; 12 wk 28 +/- 5 ng/ml) whereas 40 micrograms suppressed LH variably (basal 33 +/- 3.8; 6 wk 17 +/- 3.9; 12 wk 32 +/- 5.2). Testosterone fell to 15 +/- 2.4 and 19 +/- 2.0 ng/100 ml in response to 200 micrograms q.d. and to 27 +/- 6.4 and 22 +/- 7.4 ng/100 ml with the 40-micrograms dose. These findings in the rodent prompted treatment of stage D prostate cancer patients with similarly high doses of [D-Leu6-des-Gly-NH2(10)]-GnRH-A. After treatment for 11 wk with 1,000 or 10,000 micrograms/d of the analog, testosterone and dihydrotestosterone levels transiently rose and then fell into the surgically castrate range (testosterone 19 +/- 4.4 ng/100 ml [D-Leu6-des-Gly-NH2(10)]-GnRH-A vs. surgically castrate 11 +/- 0.9 ng/100 ml, P = NS; dihydrotestosterone 15 +/- 1.7 ng/100 ml GnRH-A vs. surgically castrate 15 +/- 4.1 ng/100 ml. P = NS). However, unlike the chronic stimulatory effect on the pituitary at lower doses, very high dose therapy resulted in profound suppression of plasma and urine LH. Plasma levels fell to the limit of assay detectability, whereas the more sensitive urinary assay detected prepubertal levels of excretion (i.e., 64 +/- 8.4 mlU/h). The highly sensitive rat interstitial cell testosterone bioassay for LH also demonstrated a marked decline in LH to undetectable levels in 17/19 subjects. Clinical results with [D-Leu6-des-Gly-NH2(10)]-GnRH-A simulate those achieved by surgical castration in men with prostatic cancer as suggested by available preliminary data.

Full text

PDF
1842

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auclair C., Givner M. L. Medrogestone and an LHRH analogue as potential combination therapy for hormone-dependent cancers. Arch Androl. 1982 Feb;8(1):21–24. doi: 10.3109/01485018208987013. [DOI] [PubMed] [Google Scholar]
  2. Baker H. W., Burger H. G., de Kretser D. M., Hudson B., O'Connor S., Wang C., Mirovics A., Court J., Dunlop M., Rennie G. C. Changes in the pituitary-testicular system with age. Clin Endocrinol (Oxf) 1976 Jul;5(4):349–372. doi: 10.1111/j.1365-2265.1976.tb01964.x. [DOI] [PubMed] [Google Scholar]
  3. Borgmann V., Hardt W., Schmidt-Gollwitzer M., Adenauer H., Nagel R. Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach? Lancet. 1982 May 15;1(8281):1097–1099. doi: 10.1016/s0140-6736(82)92279-6. [DOI] [PubMed] [Google Scholar]
  4. Bourne G. A., Regiani S., Payne A. H., Marshall J. C. Testicular GnRH receptors--characterization and localization on interstitial tissue. J Clin Endocrinol Metab. 1980 Aug;51(2):407–409. doi: 10.1210/jcem-51-2-407. [DOI] [PubMed] [Google Scholar]
  5. Byar D. P. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 1973 Nov;32(5):1126–1130. doi: 10.1002/1097-0142(197311)32:5<1126::aid-cncr2820320518>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  6. Clayton R. N. Gonadotropin-releasing hormone modulation of its own pituitary receptors: evidence for biphasic regulation. Endocrinology. 1982 Jul;111(1):152–161. doi: 10.1210/endo-111-1-152. [DOI] [PubMed] [Google Scholar]
  7. Clayton R. N., Katikineni M., Chan V., Dufau M. L., Catt K. J. Direct inhibition of testicular function by gonadotropin-releasing hormone: mediation by specific gonadotropin-releasing hormone receptors in interstitial cells. Proc Natl Acad Sci U S A. 1980 Aug;77(8):4459–4463. doi: 10.1073/pnas.77.8.4459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Corbin A. From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents. Yale J Biol Med. 1982 Jan-Feb;55(1):27–47. [PMC free article] [PubMed] [Google Scholar]
  9. Crowley W. F., Jr, Comite F., Vale W., Rivier J., Loriaux D. L., Cutler G. B., Jr Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab. 1981 Feb;52(2):370–372. doi: 10.1210/jcem-52-2-370. [DOI] [PubMed] [Google Scholar]
  10. Dahlén H. G., Keller E., Schneider H. P. Linear dose dependent LH release following intranasally sprayed LRH. Horm Metab Res. 1974 Nov;6(6):510–513. doi: 10.1055/s-0028-1093799. [DOI] [PubMed] [Google Scholar]
  11. Demers L. M., Derck D. D. Comparison of competitive protein binding analysis and radioimmunoassay for the determination of cortisol in serum and urine. Clin Biochem. 1977 Jun;10(3):104–108. doi: 10.1016/s0009-9120(77)91392-3. [DOI] [PubMed] [Google Scholar]
  12. Drago J. R., Ikeda R. M., Maurer R. E., Goldman L. B., Tesluk H. The Nb rat: prostatic adenocarcinoma model. Invest Urol. 1979 Mar;16(5):353–359. [PubMed] [Google Scholar]
  13. Dufau M. L., Pock R., Neubauer A., Catt K. J. In vitro bioassay of LH in human serum: the rat interstitial cell testosterone (RICT) assay. J Clin Endocrinol Metab. 1976 May;42(5):958–969. doi: 10.1210/jcem-42-5-958. [DOI] [PubMed] [Google Scholar]
  14. Faure N., Labrie F., Lemay A., Bélanger A., Gourdeau Y., Laroche B., Robert G. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men. Fertil Steril. 1982 Mar;37(3):416–424. doi: 10.1016/s0015-0282(16)46107-8. [DOI] [PubMed] [Google Scholar]
  15. Fontana D., Isaia G. C., Fasolis G., Bertagna A., Borgno M., Molinatti G. M. Détermination des taux plasmatiques de testostérone et des gonadotrophines hypophysaires (FSH, LH) avant et après l'intervention d'adénomectomie prostatique. J Urol Nephrol (Paris) 1979 Jul-Aug;85(7-8):479–484. [PubMed] [Google Scholar]
  16. Fraser H. M. Antifertility effects of GnRH. J Reprod Fertil. 1982 Mar;64(2):503–515. doi: 10.1530/jrf.0.0640503. [DOI] [PubMed] [Google Scholar]
  17. Fraser H. M., Lincoln G. A. Effects of chronic treatment with an LHRH agonist on the secretion of LH, FSH and testosterone in the ram. Biol Reprod. 1980 Mar;22(2):269–276. doi: 10.1095/biolreprod22.2.269. [DOI] [PubMed] [Google Scholar]
  18. Freireich E. J., Gehan E. A., Rall D. P., Schmidt L. H., Skipper H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966 May;50(4):219–244. [PubMed] [Google Scholar]
  19. Geller J., Albert J., Yen S. S., Geller S., Loza D. Medical castration of males with megestrol acetate and small doses of diethylstilbestrol. J Clin Endocrinol Metab. 1981 Mar;52(3):576–580. doi: 10.1210/jcem-52-3-576. [DOI] [PubMed] [Google Scholar]
  20. Geller J., Albert J., Yen S. S. Treatment of advanced cancer of prostate with megestrol acetate. Urology. 1978 Nov;12(5):537–541. doi: 10.1016/0090-4295(78)90467-3. [DOI] [PubMed] [Google Scholar]
  21. Glode L. M., Robinson J., Gould S. F. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet. 1981 May 23;1(8230):1132–1134. doi: 10.1016/s0140-6736(81)92301-1. [DOI] [PubMed] [Google Scholar]
  22. Harman S. M., Tsitouras P. D. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinol Metab. 1980 Jul;51(1):35–40. doi: 10.1210/jcem-51-1-35. [DOI] [PubMed] [Google Scholar]
  23. Hsueh A. J., Jones P. B. Extrapituitary actions of gonadotropin-releasing hormone. Endocr Rev. 1981 Fall;2(4):437–461. doi: 10.1210/edrv-2-4-437. [DOI] [PubMed] [Google Scholar]
  24. Johnson D. E., Kaesler K. E., Ayala A. G. Megestrol acetate for treatment of advanced carcinoma of the prostate. J Surg Oncol. 1975;7(1):9–15. doi: 10.1002/jso.2930070103. [DOI] [PubMed] [Google Scholar]
  25. Kulin H. E., Bell P. M., Santen R. J., Ferber A. J. Integration of pulsatile gonadotropin secretion by timed urinary measurements: an accurate and sensitive 3-hour test. J Clin Endocrinol Metab. 1975 May;40(5):783–789. doi: 10.1210/jcem-40-5-783. [DOI] [PubMed] [Google Scholar]
  26. Labrie F., Cusan L., Séguin C., Bélanger A., Pelletier G., Reeves J., Kelly P. A., Lemay A., Raynaud J. P. Antifertility effects of LHRH agonists in the male rat and inhibition of testicular steroidogenesis in man. Int J Fertil. 1980;25(3):157–170. [PubMed] [Google Scholar]
  27. Linde R., Doelle G. C., Alexander N., Kirchner F., Vale W., Rivier J., Rabin D. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med. 1981 Sep 17;305(12):663–667. doi: 10.1056/NEJM198109173051203. [DOI] [PubMed] [Google Scholar]
  28. London D. R., Butt W. R., Lynch S. S., Marshall J. C., Owusu S., Robinson W. R., Stephenson J. M. Hormonal responses to intranasal luteinizing hormone releasing hormone. J Clin Endocrinol Metab. 1973 Nov;37(5):829–831. doi: 10.1210/jcem-37-5-829. [DOI] [PubMed] [Google Scholar]
  29. Meldrum D. R., Chang R. J., Lu J., Vale W., Rivier J., Judd H. L. "Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab. 1982 May;54(5):1081–1083. doi: 10.1210/jcem-54-5-1081. [DOI] [PubMed] [Google Scholar]
  30. Murray F. T., Osterman J., Sulewski J., Page R., Bergland R., Hammond J. M. Pituitary function following surgery for prolactinomas. Obstet Gynecol. 1979 Jul;54(1):65–73. doi: 10.1097/00006250-197907000-00016. [DOI] [PubMed] [Google Scholar]
  31. Musto N. A., Santen R. J., Huckins C., Bardin C. W. Abnormalities of the pituitary-gonadal-axis of Hre rats: a study of animals with an inherited disorder of seminiferous tubular and Leydig cell function. Biol Reprod. 1978 Nov;19(4):797–806. doi: 10.1095/biolreprod19.4.797. [DOI] [PubMed] [Google Scholar]
  32. Redding T. W., Schally A. V. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6509–6512. doi: 10.1073/pnas.78.10.6509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Resko J. A., Belanger A., Labrie F. Effects of chronic treatment with a potent luteinizing hormone releasing hormone agonist on serum luteinizing hormone and steroid levels in the male rhesus monkey. Biol Reprod. 1982 Apr;26(3):378–384. doi: 10.1095/biolreprod26.3.378. [DOI] [PubMed] [Google Scholar]
  34. Rivier C., Rivier J., Vale W. Chronic effects of [D-Trp6,Pro9-NEt]luteinizing hormone-releasing factor on reproductive processes in the male rat. Endocrinology. 1979 Nov;105(5):1191–1201. doi: 10.1210/endo-105-5-1191. [DOI] [PubMed] [Google Scholar]
  35. Rost A., Schmidt-Gollwitzer M., Hantelmann W., Brosig W. Cyproterone acetate, testosterone, LH, FSH, and prolactin levels in plasma after intramuscular application of cyproterone acetate in patients with prostatic cancer. Prostate. 1981;2(3):315–322. doi: 10.1002/pros.2990020310. [DOI] [PubMed] [Google Scholar]
  36. Rubens R., Dhont M., Vermeulen A. Further studies on Leydig cell function in old age. J Clin Endocrinol Metab. 1974 Jul;39(1):40–45. doi: 10.1210/jcem-39-1-40. [DOI] [PubMed] [Google Scholar]
  37. Samojlik E., Santen R. J. Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma. J Clin Endocrinol Metab. 1978 Oct;47(4):717–724. doi: 10.1210/jcem-47-4-717. [DOI] [PubMed] [Google Scholar]
  38. Sandow J., Hahn M. Chronic treatment with LH-RH in golden hamsters. Acta Endocrinol (Copenh) 1978 Jul;88(3):601–610. doi: 10.1530/acta.0.0880601. [DOI] [PubMed] [Google Scholar]
  39. Santen R. J. Is aromatization of testosterone to estradiol required for inhibition of luteinizing hormone secretion in men? J Clin Invest. 1975 Dec;56(6):1555–1563. doi: 10.1172/JCI108237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Santner S. J., Santen R. J., Kulin H. E., Demers L. M. A model for validation of radioimmunoassay kit reagents: measurement of follitropin and lutropin in blood and urine. Clin Chem. 1981 Nov;27(11):1892–1895. [PubMed] [Google Scholar]
  41. Schmidt J. D., Scott W. W., Gibbons R., Johnson D. E., Prout G. R., Jr, Loening S., Soloway M., deKernion J. B., Pontes J. E., Slack N. H. Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer. 1980 Apr 15;45(7 Suppl):1937–1946. [PubMed] [Google Scholar]
  42. Silverberg E. Cancer statistics, 1982. CA Cancer J Clin. 1982 Jan-Feb;32(1):15–31. [PubMed] [Google Scholar]
  43. Solano A. R., Dufau M. L., Catt K. J. Bioassay and radioimmunoassay of serum luteinizing hormone in the male rat. Endocrinology. 1979 Aug;105(2):372–381. doi: 10.1210/endo-105-2-372. [DOI] [PubMed] [Google Scholar]
  44. Sparrow D., Bosse R., Rowe J. W. The influence of age, alcohol consumption, and body build on gonadal function in men. J Clin Endocrinol Metab. 1980 Sep;51(3):508–512. doi: 10.1210/jcem-51-3-508. [DOI] [PubMed] [Google Scholar]
  45. Stearns E. L., MacDonnell J. A., Kaufman B. J., Padua R., Lucman T. S., Winter J. S., Faiman C. Declining testicular function with age. Hormonal and clinical correlates. Am J Med. 1974 Nov;57(5):761–766. doi: 10.1016/0002-9343(74)90850-x. [DOI] [PubMed] [Google Scholar]
  46. Sundaram K., Connell K. G., Bardin C. W., Samojlik E., Schally A. V. Inhibition of pituitary-testicular function with [D-Trp6] luteinizing hormone-releasing hormone in rhesus monkeys. Endocrinology. 1982 Apr;110(4):1308–1314. doi: 10.1210/endo-110-4-1308. [DOI] [PubMed] [Google Scholar]
  47. Séguin C., Bélanger A., Cusan L., Pelletier G., Reeves J. J., Lefebvre F. A., Kelly P. A., Labrie F. Relative importance of the adenohypophyseal and gonadal sites in inhibitory action of LHRH agonists. Biol Reprod. 1981 May;24(4):889–901. doi: 10.1095/biolreprod24.4.889. [DOI] [PubMed] [Google Scholar]
  48. Séguin C., Cusan L., Bélanger A., Kelly P. A., Labrie F., Raynaud J. P. Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat. Mol Cell Endocrinol. 1981 Jan;21(1):37–41. doi: 10.1016/0303-7207(81)90028-9. [DOI] [PubMed] [Google Scholar]
  49. Tcholakian R. K., de la Cruz A., Chowdhury M., Steinberger A., Coy D. H., Schally A. V. Unusual anti-reproductive properties of the analog [d-Leu6,des-Gly-NH2(10)]-luteinizing hormone-releasing hormone ethylamide in male rats. Fertil Steril. 1978 Nov;30(5):600–603. [PubMed] [Google Scholar]
  50. Teodorczyk-Injeyan J., Jewett M. A., Kellen J. A., Malkin A. Gonadoliberin (LHRH) mediated release of choriogonadotropin in experimental human and animal tumors in vitro. Endocr Res Commun. 1981;8(1):19–24. doi: 10.1080/07435808109065980. [DOI] [PubMed] [Google Scholar]
  51. Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A. T., Comaru-Schally A. M., Schally A. V. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658–1662. doi: 10.1073/pnas.79.5.1658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Tolis G., Mehta A., Comaru-Schally A. M., Schally A. V. Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man. J Clin Invest. 1981 Sep;68(3):819–822. doi: 10.1172/JCI110320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Vickery B. H., McRae G. I., Bonasch H. Effect of chronic administration of a highly potent LHRH agonist on prostate size and secretory function in geriatric dogs. Prostate. 1982;3(2):123–130. doi: 10.1002/pros.2990030204. [DOI] [PubMed] [Google Scholar]
  54. Vilchez-Martinez J. A., Coy D. H., Arimura A., Coy E. J., Hirotsu Y., Schally A. V. Synthesis and biological properties of (Leu-6)-LH-RH and (D-Leu-6,desGly-NH210)-LH-RH ethylamide. Biochem Biophys Res Commun. 1974 Aug 19;59(4):1226–1232. doi: 10.1016/0006-291x(74)90445-8. [DOI] [PubMed] [Google Scholar]
  55. de la Torre B., Sjöberg B., Hedman M., Bártfai G., Diczfalusy E. A study of the short-time variation and interrelationship of plasma hormone levels reflecting pituitary, adrenocortical and testicular function in fertile men. Int J Androl. 1981 Oct;4(5):532–545. doi: 10.1111/j.1365-2605.1981.tb00736.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES